Vanguard Group Inc. Buys 16,095 Shares of Insulet Co. (NASDAQ:PODD)

Vanguard Group Inc. raised its position in Insulet Co. (NASDAQ:PODD) by 0.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 8,489,976 shares of the medical instruments supplier’s stock after buying an additional 16,095 shares during the period. Vanguard Group Inc. owned about 0.12% of Insulet worth $2,216,478,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. SBI Securities Co. Ltd. bought a new position in Insulet in the fourth quarter valued at about $36,000. SRS Capital Advisors Inc. lifted its position in Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after purchasing an additional 56 shares during the period. Friedenthal Financial bought a new position in shares of Insulet in the 4th quarter valued at about $57,000. TD Private Client Wealth LLC grew its position in shares of Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after buying an additional 56 shares during the period. Finally, Assetmark Inc. lifted its holdings in Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier’s stock valued at $69,000 after buying an additional 246 shares during the period.

Insider Transactions at Insulet

In related news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of the firm’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now owns 3,231 shares of the company’s stock, valued at approximately $888,525. This represents a 36.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.47% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on PODD. Citigroup upped their target price on shares of Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Raymond James reissued an “outperform” rating and issued a $328.00 target price (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. Royal Bank of Canada started coverage on Insulet in a research report on Thursday, March 6th. They set an “outperform” rating and a $340.00 target price for the company. StockNews.com cut Insulet from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th. Finally, TD Cowen boosted their price objective on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a report on Friday, January 3rd. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus price target of $292.06.

Insulet Trading Down 2.9 %

NASDAQ PODD opened at $264.88 on Thursday. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock’s 50 day moving average price is $272.28 and its two-hundred day moving average price is $258.24. The stock has a market capitalization of $18.60 billion, a price-to-earnings ratio of 45.75, a PEG ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. As a group, analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.